Kolon TissueGene (950160) plunged to the 20,000-won level, recording its lower limit for three consecutive trading days. On the same day, both the KOSPI and KOSDAQ surged 4–5%, staging a strong rally, but Kolon TissueGene moved in the exact opposite direction of the market trend and could not escape selling pressure.

3rd Consecutive Lower Limit, Closing at 21,050 Won

On the 23rd, Kolon TissueGene closed at 21,050 won, down 9,000 won (29.95%) from the previous trading day. This marks three consecutive trading days of falling by the daily price limit, following the 21st and 22nd.

On the same day, the domestic stock market showed overall strength. The KOSPI closed at 7,096.89, up 299.19 points (4.40%) from the previous trading day, while the KOSDAQ finished at 790.28, up 39.19 points (5.21%). However, Kolon TissueGene continued its extreme weakness, unaffected by the broader market's risk-on sentiment.

Closing Price Falls to Less Than One-Third in 5 Trading Days

The stock's decline has become increasingly pronounced over time. Kolon TissueGene closed at 77,900 won on the 15th, then fell 20.28% on the 16th and another 1.45% on the 20th. Subsequently, it recorded lower limits for three consecutive trading days from the 21st to the 23rd, extending its losing streak to five trading days.

Notably, compared to the closing price on the 15th (77,900 won), the closing price on this day has dropped to a level that does not even reach one-third in just five trading days.

Investor Sentiment Cools Sharply After TG-C Clinical Trial Results

This sharp decline is interpreted as the continued impact of a rapid cooling in investor sentiment after the initial results from the U.S. Phase 3 clinical trial of 'TG-C,' a cell and gene therapy for osteoarthritis, failed to meet market expectations.

In the market, some project that given the significantly expanded price volatility due to the short-term plunge, future additional disclosures, subsequent clinical trial schedules, and the recovery of investor sentiment will serve as key variables for the stock price.

[This article is not intended to solicit investment. All final investment decisions and responsibilities lie with the investor.]